Journals / Zeynep Kamil Tıp Bülteni / 2018 / Cilt: 49 - Sayı: 4

The Survival Effect of Residual Disease on Hysterectomy Specimen Among the Patients Previously Treated by Chemoradiotherapy

Serviks Kanserinde Primer Kemoradyoterapi Sonrası Uterusta Sınırlı Rezidu Tümörün Sağkalıma Olan Etkisi

Pages
348–352
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Increasing size of residual tumour proven by histopathological method on uterus is associated with worse prognosis.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Objective: to determine the association between the life prospects and residual tumour size on hysterectomy specimen among the group of patients previously treated by primary chemoradiotherapy.
📊
Key Findings & Data:Material and Methods: thirty one patients operated at istanbul university istanbul medical faculty between 2009 april and 2017 october due to insuffient treatment after primary chemoradiotherapy are recruited.
💡
Conclusion & Impact:Increasing size of residual tumour proven by histopathological method on uterus is associated with worse prognosis.
🔬Design:Research Article
📍Scope:2009 Verileri
⚙️Variables:Domain Parameters

Abstract

Objective: to determine the association between the life prospects and residual tumour size on hysterectomy specimen among the group of patients previously treated by primary chemoradiotherapy. Secondary aim of the study is to investigate the success of imaging methods on the same group of patients. Material and Methods: thirty one patients operated at istanbul university istanbul medical faculty between 2009 april and 2017 october due to insuffient treatment after primary chemoradiotherapy are recruited. Clinicopatholigical features of these patients were evaluated. Patients are categorized according to residual tumour size on hysterectomy specimen i) no residual tumour in specimen ii) residual tumour size under 10 mm iii) residual tumour size more than 10 mm. Results: Median age is calculated as 54 . Sensitivity and specifity of magnetic resonance investigation are found 75 percent and 50 percent whereas pozitron emission tomography sensitivity and specifity are calculated as 54 and 50 percent espectively. One year disease free survival of no tumour group, microscopic tumour group and macroscopic tumour group are calculated 92 , 80, 38 percent, respectively. Conclusion: The success of imaging methods on determining residual tumour in uterus is limited. Increasing size of residual tumour proven by histopathological method on uterus is associated with worse prognosis.

Özet

Amaç: Primer kemoradyoterapi tedavisi almış ileri evre serviks kanserli hastalarda uterusa sınırlı rezidü tümör miktarının sağkalıma etkisini belirlemek ve bu tarz tümörlerde görüntüleme yöntemlerinin rezidü tümör saptamadaki başarısı saptamak. Gereçler ve Yöntem: İstanbul Universitesi İstanbul Tıp Fakültesi Jinekolojik Onkoloji Kliniğinde 2009 Nisan-2017 Mayıs ayları arasında opere edilen 31 hasta çalışmaya dahil edilmiştir. Bu hastaların klinikopatolojik özellikleri değerlendirilmiştir. Hastalar operasyon öncesi Magnetik Rezonans inceleme (MRI) ve/veya Pozitron Emisyon Tomografi (PET-BT) ile değerlendirilmiştir. Hastalar operasyon sonrası uterus materyalinde tümör miktarına göre i) rezidu tümör yok ii) rezidü tümör 10 mm olarak üç gruba ayrılmış ve hastalıksız sağkalım incelemesi yapılmıştır. Bulgular: Ortanca yaş 54 olarak hesaplanmıştır. MRI rezidü tümör saptamada sensitivitesi %75 spesifitesi %50 ; PET-BT sensitivitesi %54.5 spesifitesi %50 olarak saptanmıştır. Bir yıllık hastalıksız sağkalım oranları rezidü olmayan, mikroskobik rezidü olan ve makroskobik rezidü olan hastalarda sırası ile %92.3, %80 ve %38.5 olarak tespit edildi. Sonuç: Irradiye serviks kanserinde rezidü tümör saptamada görüntüleme yöntemlerinin başarısı kısıtlıdır. Histopatolojik olarak saptanmış rezidü tümörün büyüklüğü arttıkça hastalıksız sağkalım rakamları azalmaktadır.

🔖

Cite This Article

SÖZEN, H., BAKTIROGLU, M., YUMLU, H., USTA, İ., YALÇIN, İ., İBİŞ, K., KÜÇÜCÜK, S., TOPUZ, S., SALİHOĞLU, Y. (2018). The Survival Effect of Residual Disease on Hysterectomy Specimen Among the Patients Previously Treated by Chemoradiotherapy. Zeynep Kamil Tıp Bülteni, Cilt: 49 - Sayı: 4, 348–352. https://ajindex.com/articles/335422

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (9)

  1. Gültekin M, Küçükyıldız I, Karaca M, Trends of Gynecological Cancers in Turkey Toward Europe or Asia? Int J Gynecol Cancer 2017;27: S1YS9 Green JA, Kirwan JM, Tierney JF, et al. Survival and recurrence afterconcomitant chemotherapy and radiotherapy for cancer of the uterine cervix: a systematic review and meta-analysis. Lancet 2001;358:781–6. Chemoradiotherapy for Cervical Cancer Meta-Analysis Collaboration. Reducing uncertainties about the effects of chemoradiotherapy for cervical cancer: a systematic review and meta-analysis of individual patient data from 18 randomized trials. J Clin Oncol 2008;26:5802–12.
  2. Sturdza A, Potter R, Fokdal LU et al (2016) Image guided brachytherapy in locally advanced cervical cancer: improved pelvic control and survival in RetroEMBRACE, a multicenter cohort study. Radiother Oncol 120:428–433
  3. Keys HM, Bundy BN, Stehman FB, Okagaki T, Gallup DG, Burnett AF,Rotman MZ, Fowler WC Jr, Gynecologic Oncology Group: Gynecologic Oncology Group. Radiation therapy with and without extrafascial hysterectomy for bulky stage IB cervical carcinoma: a randomized trial of the Gynecologic Oncology Group. Gynecol Oncol 2003, 89:343-353.
  4. Carcopino X, Houvenaeghel G, ButtarelliMet al (2008) Equivalentsurvival in patients with advanced stage IB-II and III-IVA cervical cancer treated by adjuvant surgery following chemoradiotherapy.Eur J Surg Oncol 34:569–575
  5. Hass P, Eggemann H, Costa S et al. Adjuvant hysterectomy after radiochemotherapy for locally advanced cervical cancer Strahlenther Onkol (2017) 193:1048–1055
  6. G. Ferrandina, P.A.Margariti, D. Smaniotto,M. Petrillo, M.G. Salerno, A. Fagotti, et al., Long-term analysis of clinical outcome and complications in locally advanced cervical cancer patients administered concomitant chemoradiation followed by radicalsurgery, Gynecol. Oncol. 119 (2010) 404–410.
  7. D. Hequet, E. Marchand, V. Place, V. Fourchotte, A. De La Rochefordiere, S. Dridi, et al., Evaluation and impact of residual disease in locally advanced cervical cancer after concurrent chemoradiation therapy: results of a multicenter study, Eur. J. Surg. Oncol. 39 (2013) 1428–1434.
  8. Valduvieco I, Biete A, Rios I. Et al. Correlation between clinical findings and magnetic resonance imaging fort he assesment of local response after standard treatment in cervical cancer. Rep Pract Oncol Radiother 2013;18:214-9
  9. E. Vincens, C. Balleyguier, A. Rey, C. Uzan, E. Zareski, S. Gouy, et al., Accuracy of magnetic resonance imaging in predicting residual disease in